Profiling proteomic responses in small intestinal neuroendocrine tumor GOT1 after [177Lu]Lu-DOTATATE therapy
Johan K.E. Spetz, Mikael E. Montelius, Evelin Berger, Julia A.M. Johansson, Nishte Rassol, Maria Ljungberg, Eva B. Forssell-Aronsson · 2026
Read Profiling proteomic responses in small intestinal neuroendocrine tumor GOT1 after [177Lu]Lu-DOTATATE therapy by Johan K.E. Spetz, Mikael E. Montelius, Evelin Berger, Julia A.M. Johansson, Nishte Rassol, Maria Ljungberg, Eva B. Forssell-Aronsson (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13584284.txt.
Description
Johan Spetz and co-authors profile protein changes in a small intestinal neuroendocrine tumor model after radioactive targeted therapy. Their 2026 study uses the GOT1 tumor line and the drug Lu-DOTATATE, an established treatment for such tumors.
The therapy has strong anti-tumor effects in models, yet curative responses in patients stay limited. Mice bearing GOT1 tumors got a non-curative dose of the drug or a saline control. Tumors were collected one day and thirteen days after treatment, to represent early and later responses. Proteomic profiling then mapped which proteins rose or fell. Knowing the molecular response may point to ways to improve the therapy.
Catalog record
| CREATOR | Johan K.E. Spetz, Mikael E. Montelius, Evelin Berger, Julia A.M. Johansson, Nishte Rassol, Maria Ljungberg, Eva B. Forssell-Aronsson |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 44 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |